HASBROUCK HEIGHTS, N.J., May 20, 2010 (GLOBE NEWSWIRE) -- Nymox Pharmaceutical Corporation (Nasdaq:NYMX) is pleased to announce that a symposium and panel discussion devoted to progress in the development of NX-1207, the Company’s Phase 3 drug for benign prostatic hyperplasia (BPH), will be held at the 2010 Annual Meeting of the American Urological Association which begins May 29 in San Francisco. The symposium, entitled “Progress with NX-1207: Phase 3 Pro-Apoptotic Injectable for BPH,” will be chaired by Dr. Neal Shore, a U.S. expert in prostate diseases, and will also include several other well known authorities and practitioners in the field. More information will be made available next week at the time of the meeting.
